I’ve read it all now. It goes over everything of pertinence and discusses the competitors, and also how their success might actually lead to some recognition of our potential success. And think of all all the slides you’ve ever seen ….a lot of them are in it. Bottom line… PYC has been overlooked by the masses of biotech investors, it has a reasonable to good chance of getting a drug to market, the drugs are in the protected orphan space which comes with quite a few perks, and worst case we will be in the 30c plus range by this time next year, but probably at $1 a couple of years later. So….
it is complicated, but we get closer to the rerate point with each day.
PYC - General Discussion, page-139
-
- There are more pages in this discussion • 350 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.3¢ |
Change
-0.003(1.72%) |
Mkt cap ! $653.2M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.5¢ | $607.2K | 4.331M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 521762 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 389298 | 10 |
View Market Depth
| Last trade - 15.38pm 13/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |